HER2 exon 20 insertion

Overview

HER2 exon 20 insertion refers to an activating alteration in the ERBB2 gene, which encodes human epidermal growth factor receptor 2 (HER2), a receptor tyrosine kinase involved in cell growth and signaling. Exon 20 insertions are a class of in-frame insertion mutations that can alter receptor conformation and promote oncogenic signaling. In clinical oncology, HER2 exon 20 insertion is most prominently discussed in non-small cell lung carcinoma (NSCLC), where it is recognized as a therapeutically relevant molecular subtype and a target for HER2-directed treatment strategies.

Biologically, HER2 is a major therapeutic target in cancer because it can drive downstream signaling pathways such as ERK-mediated proliferation and survival. Although HER2 exon 20 insertion is distinct from HER2 amplification or overexpression, it is still clinically important because it can confer sensitivity to selected HER2-targeted agents, including antibody-drug conjugates. At the same time, HER2-directed therapy can be associated with toxicity, and the mutation has been studied in the context of treatment response and adverse events.

Recent Publications Summary

Recent publications involving HER2 exon 20 insertion focused primarily on therapeutic management in non-small cell lung cancer and on broader HER2-directed drug development. A case report described a 78-year-old woman with NSCLC harboring a HER2 exon 20 insertion who developed grade 1 trastuzumab deruxtecan (T-DXd)–induced interstitial lung disease during third-line treatment; after corticosteroid therapy and radiologic improvement, T-DXd was successfully re-administered at a reduced dose, and the patient received eight additional cycles with tumor regression and no ILD recurrence 41192915Nov. This report emphasized the importance of early ILD detection and management to preserve the benefit of HER2-targeted therapy in this molecular subgroup 41192915Nov.

Other recent studies did not directly evaluate HER2 exon 20 insertion, but they provide context for HER2-targeted approaches relevant to this alteration. One pharmacokinetic study assessed zongertinib, an irreversible HER2-selective tyrosine kinase inhibitor, and examined the effect of the strong CYP3A inhibitor itraconazole on its exposure in healthy volunteers 42324472Jun. Additional work on HER2-directed antibody-drug conjugates in breast cancer used circulating tumor cells to monitor HER2 expression dynamics during T-DXd therapy, finding marked heterogeneity of HER2 expression and showing that early reductions in CTC burden, rather than baseline HER2 epitope levels, were associated with durable response 42308036Jun.

Several mechanistic and platform studies further expanded HER2-targeted research. An optogenetic antibody platform demonstrated stimulus-gated antigen recognition against HER2 among other targets, supporting externally controlled antigen binding and cell signaling 42102802May. A proximity-catalyzed in situ anchoring strategy used HER2 as a proof-of-concept membrane biomarker for fluorescence-guided delineation of minimal residual disease in breast cancer surgery 42224475Jun. Separately, engineering of bispecific VHH domains enabled dual binding to HER2-containing target combinations, illustrating a modular approach to multivalent HER2 recognition 42152502May.

What Changes, What Holds

1. Rechallenge after lung toxicity can preserve benefit in HER2 exon 20 insertion NSCLC
NEW DIRECTION A case report suggests that trastuzumab deruxtecan–related interstitial lung disease does not always end use of HER2-directed therapy in this setting; with prompt steroid treatment, radiologic recovery, and dose reduction, treatment was resumed without recurrent ILD and with ongoing tumor regression 41192915Nov. That adds a practical management option to the baseline, which already recognized both therapeutic relevance and toxicity, but it remains single-patient evidence and does not define who can be safely rechallenged.

2. HER2-directed development is broadening beyond direct exon 20 insertion data
METHOD Recent work here does not change what HER2 exon 20 insertion is or how it is currently treated; instead, it extends the research toolkit around HER2-targeted therapy. Pharmacokinetic interaction testing for zongertinib and circulating-tumor-cell monitoring during T-DXd illustrate how exposure, target dynamics, and response may be studied more precisely 42324472Jun42308036Jun. For the baseline, this mainly refines drug-development context rather than adding mutation-specific clinical evidence.

3. New HER2 platforms expand targeting and detection strategies without altering the mutation’s clinical meaning
METHOD Optogenetic antigen recognition, fluorescence-guided residual disease mapping, and bispecific VHH engineering all use HER2 as a model or target, but they do not revise the established account of HER2 exon 20 insertion as an activating ERBB2 alteration relevant in NSCLC 42102802May42224475Jun42152502May. Their significance is methodological: they point to more controllable binding, better surgical visualization, and modular multivalent recognition. None of these findings yet changes the baseline therapeutic interpretation of the mutation itself.

Overview update candidates: rechallenge after trastuzumab deruxtecan–induced ILD in HER2 exon 20 insertion NSCLC may merit mention as a management nuance; but the other findings are methodological context rather than overview-level additions.